The United States, Japan, and China have already approved
the use of lecanemab, with the UK recently joining them. This approval marks a
big step in the global adoption of Alzheimer’s treatment. This could be a
reflection of growing international confidence in lecanemab’s potential
benefits.
The United States, Japan, and China have already approved
the use of lecanemab, with the UK recently joining them. This approval marks a
big step in the global adoption of Alzheimer’s treatment. This could be a
reflection of growing international confidence in lecanemab’s potential
benefits.